Could a new drug quiet the ringing and dizziness of Meniere's disease?

NCT ID NCT02603081

Completed Symptom relief Sponsor: Sound Pharmaceuticals, Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SPI-1005 (ebselen) in adults with Meniere's disease, a condition that causes vertigo, tinnitus, and hearing loss. The trial compares three doses of SPI-1005 against a placebo to see if it safely reduces these symptoms. Researchers will monitor side effects, drug levels in the blood, and changes in hearing and balance over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPI-1005 (ebselen)
What this could lead to: If successful, SPI-1005 could offer a new treatment option to reduce vertigo attacks and hearing loss in people with Meniere's disease.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENIERE'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hearing loss disorder Meniere disease Tinnitus Vertigo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENIERE'S DISEASE

Contacts and locations

Locations

House Clinic

Los Angeles, California, 90057, United States
MUSC

Charleston, South Carolina, 29425, United States
New York Otology

New York, New York, 10028, United States
Northwest Ear

Seattle, Washington, 98104, United States
Sound Pharmaceuticals, Inc.

Seattle, Washington, 98103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.